WRBY · available-data snapshot
Warby Parker Inc. (WRBY): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Warby Parker Inc. (WRBY); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for WRBY?
We do not publish a fair value for Warby Parker Inc.. What we can say from its filings and market data is below.
What is WRBY's TickerWorth Score?
Priced far above peers — the business scores well
Compared with Healthcare companies in US
Its strongest point: growing quickly. Its weakest: trades above our estimate of what it's worth.
- Value · 24 of 100
Cheaper than 24% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 34 of 100
More profitable than 34% of Healthcare companies in US
- Financial health · 60 of 100
Financially stronger than 60% of Healthcare companies in US
- Growth · 78 of 100
Growing faster than 78% of Healthcare companies in US
- Momentum · 48 of 100
Outperformed 48% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $24.46
- Market cap
- $3,
024, 071, 168 - 52-week high
- $31.00
- 52-week low
- $14.96
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Warby Parker Inc. (WRBY) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, WRBY trades at a recent price of $24.46, a market capitalisation of about $3,024,071,168, sitting 59% of the way up its 52-week range ($14.96–$31.00), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing WRBY's trading multiples against a sector benchmark. Here that gives P/E of 407.8× (richer than the peer median of 42.2×); Fwd P/E of 39.8× (richer than the peer median of 17.6×); P/B of 7.7× (in line with the peer median of 7.9×); P/S of 3.3× (cheaper than the peer median of 6.2×); EV/EBITDA of 68.6× (richer than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. WRBY shows a price-to-book (P/B) of 7.70 and book value of $3.18 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. WRBY is in a mixed trend, trading -21.1% from its 52-week high. Over the past year the stock is +7.2%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
WRBY vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | WRBY | Peer median | Read |
|---|---|---|---|
| P/E | 407.8× | 42.2× | richer than |
| Fwd P/E | 39.8× | 17.6× | richer than |
| P/B | 7.7× | 7.9× | in line with |
| P/S | 3.3× | 6.2× | cheaper than |
| EV/EBITDA | 68.6× | 18.5× | richer than |
What does Warby Parker Inc. do?
What does it do?
Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in United States. The company employs roughly 2,275 people.
How does it make money?
The business turns $912M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -3.6%), after a 53% gross margin on the products/services it sells. After all costs, taxes and interest, 0.8% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.6× equity), comfortably covers its short-term bills (2.3× current ratio), and is currently profitable.
Who at WRBY filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Raider Jeffrey Jacob | Director | Open-market sale | $415,500.00 | Form 4 for Raider Jeffrey Jacob (opens sec.gov in a new tab) | |
| Blumenthal Neil Harris | Director, Co-Chief Executive Officer | Conversion | — | Form 4 for Blumenthal Neil Harris (opens sec.gov in a new tab) | |
| Blumenthal Neil Harris | Director, Co-Chief Executive Officer | Open-market sale | $2,769,000.00 | Form 4 for Blumenthal Neil Harris (opens sec.gov in a new tab) | |
| Blumenthal Neil Harris | Director, Co-Chief Executive Officer | Option exercise | — | Form 4 for Blumenthal Neil Harris (opens sec.gov in a new tab) | |
| Blumenthal Neil Harris | Director, Co-Chief Executive Officer | Option exercise | — | Form 4 for Blumenthal Neil Harris (opens sec.gov in a new tab) | |
| Blumenthal Neil Harris | Director, Co-Chief Executive Officer | Shares withheld (tax) | $278,281.76 | Form 4 for Blumenthal Neil Harris (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.